×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu
Martin Conlon

Martin Conlon

Martin is Head of Australian Equities at Schroders. He is a fund manager and involved in the portfolio construction process for Australian Equity portfolios, while also retaining analytical responsibilities for the Diversified Financials, Gaming, General Insurance, Life insurance and Telecommunications sectors. Martin joined Schroders in 1994 and was promoted to Head of Australian Equities in 2003. Prior to joining Schroders he was an accountant at Ernst & Young. Martin holds a Bachelor of Economics from Macquarie University, a Graduate Diploma in Applied Finance and Investment and is a qualified Chartered Accountant.

Funds / Markets

Pouring Fuel on the Fire

March 8, 2021March 8, 2021 - by Martin Conlon

Australian companies have reported generally solid results as JobKeeper flows through to revenues, while central banks continue to pour fuel on the fire underneath asset prices.

Read More
Funds / Markets

Optimistic Investing Belies an Uncertain Outlook

January 19, 2021January 20, 2021 - by Martin Conlon

Reasonable financial market returns masked a tumultuous year as investors continue to search for patterns in the market’s erratic behaviour. More surprises rolled in over December, with share prices oscillating wildly, commodity prices remaining depressed and cheap valuations overtaking business fundamentals.

Read More
Markets / Video

Opportunities And Risks In The Market

September 9, 2020September 9, 2020 - by Martin Conlon

Following up on his wrap on Q2 Reporting Season, Martin Conlon from Schroders gives his thoughts on where some opportunities lie in the current market.

Read More
Funds / Video

Schroders Australia: Q2 2020 Reporting Season Wrap

September 4, 2020September 4, 2020 - by Martin Conlon

Q2 2020 reporting season for Australian equities has come and gone. What does that mean for investors? Who were the winners and losers? Martin Conlon, Head of Australian Equities at Schroders, gives some insights.

Read More

Recently Added

  • Evening Report: Aussie shares edged higher on Friday
  • Coronado Beset By Poor Prices, Higher Costs
  • Resumption of Normal Life No Boon for Kogan
  • Lunch Report: Market at risk to snap 4-week winning streak
  • Relief Rally Sees AMP Bounce off Record Lows
  • Archegos, Greensill the Gifts that Keep on Taking for CS
  • Morning Report: US sharemarkets fell on Thursday
  • Brambles on Track to Meet Full-Year Forecast

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

Do Two A+ Deals Foreshadow THE DEAL?

Licensing deals are the life blood of small pharmaceutical companies, representing their exit from the development of a molecule, often in a staged manner, and a coalescing of the value they have added to a compound. Kazia Therapeutics has done two licensing deals in the space of a month, something unique for an Australian company. In this report, we look at those deals, assess their quality and look at other takeaways they provide.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Tree.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Car.

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the House.

DOWNLOAD RESEARCH REPORT

The EV Megatrend – Responsibly sourced lithium the “new oil”

Lake Resources (LKE.AX) aims to become a major global producer of high quality battery grade lithium carbonate. It holds 100% equity in four significant Argentinian brine assets situated in the Lithium Triangle. LKE is using disruptive lithium extraction technology to produce lithium for sales into the US, Europe and Asia. With its clean tech partner Lilac Solutions, LKE is moving fast to bring a low carbon, low water, low waste, no acid products, light footprint, low-cost and high value project to market.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Truck.